KETOCONAZOLE- ketoconazole cream
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.

KETOCONAZOLE CREAM 2%
Rx only

DESCRIPTION
Ketoconazole Cream 2%, for topical administration only, contains the broad-spectrum synthetic antifungal agent, ketoconazole 2%, formulated in an aqueous cream vehicle consisting of propylene glycol, stearyl and cetyl alcohols, sorbitan monostearate, polysorbate 60, isopropyl myristate, sodium sulfite anhydrous, polysorbate 80 and purified water.

Ketoconazole is cis-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine and has the following structural formula:

```
\begin{center}
\includegraphics[width=0.5\textwidth]{structural_formula.png}
\end{center}
```

CLINICAL PHARMACOLOGY
When Ketoconazole Cream 2% was applied dermally to intact or abraded skin of Beagle dogs for 28 consecutive days at a dose of 80 mg, there were no detectable plasma levels using an assay method having a lower detection limit of 2 ng/ml.

After a single topical application to the chest, back and arms of normal volunteers, systemic absorption of ketoconazole was not detected at the 5 ng/ml level in blood over a 72-hour period.

Two dermal irritancy studies, a human sensitization test, a phototoxicity study and a photoallergy study conducted in 38 male and 62 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no irritation, no phototoxicity and no photoallergenic potential due to Ketoconazole Cream 2%.

Microbiology: Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the in vitro growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum and Epidermophyton floccosum; yeasts: Candida albicans, Malassezia ovale (Pityrosporum ovale) and C. tropicalis; and the organism responsible for tinea versicolor, Malassezia furfur (Pityrosporum orbiculare). Only those organisms listed in the INDICATIONS AND USAGE Section have been proven to be clinically affected. Development of resistance to ketoconazole has not been reported.

Mode of Action: In vitro studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is postulated that the therapeutic effect of ketoconazole in seborrheic dermatitis is due to the reduction of M. ovale, but this has not yet been proven.

INDICATIONS AND USAGE
Ketoconazole Cream 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis.

CONTRAINDICATIONS
Ketoconazole Cream 2% is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation.

WARNINGS
Ketoconazole Cream 2% is not for ophthalmic use.

Ketoconazole Cream 2% contains sodium sulfite anhydrous, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

PRECAUTIONS
General: If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued. Hepatitis (1:10,000 reported incidence) and, at high doses, lowered testosterone and ACTH induced corticosteroid serum levels have been seen with orally administered ketoconazole; these effects have not been seen with topical ketoconazole.

Carcinogenesis, Mutagenesis, Impairment of Fertility: A long-term feeding study in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. The dominant lethal mutation test in male and female mice revealed that single oral doses of ketoconazole as high as 80 mg/kg produced no mutation in any stage of germ cell development. The Ames'Salmonella microsomal activator assay was also negative.

Pregnancy: Teratogenic effects: Pregnancy Category C:
Ketoconazole has been shown to be teratogenic (syndactylyia and oligodactylyia) in the rat when given orally in the diet at 80 mg/kg/day, (10 times the maximum recommended human oral dose). However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels.

There are no adequate and well-controlled studies in pregnant women. Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers: It is not known whether Ketoconazole Cream 2% administered topically could result in sufficient systemic absorption to produce detectable quantities in breast milk. Nevertheless, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use: Safety and effectiveness in children have not been established.

ADVERSE REACTIONS
During clinical trials 45 (5.0%) of 905 patients treated with Ketoconazole Cream 2% and 5 (2.4%) of 208 patients treated with placebo reported side effects consisting mainly of severe irritation, pruritus and stinging. One of the patients treated with Ketoconazole Cream developed a painful allergic reaction.

In worldwide postmarketing experience, rare reports of contact dermatitis have been associated with Ketoconazole Cream or one of its excipients, namely sodium sulfite or propylene glycol.
DOSAGE AND ADMINISTRATION

Cutaneous candidiasis, tinea corporis, tinea cruris, tinea pedis and tinea (pityriasis) versicolor: It is recommended that Ketoconazole Cream 2% be applied once daily to cover the affected and immediate surrounding area. Clinical improvement may be seen fairly soon after treatment is begun; however, candidal infections and tinea cruris and corporis should be treated for two weeks in order to reduce the possibility of recurrence. Patients with tinea versicolor usually require two weeks of treatment. Patients with tinea pedis require six weeks of treatment. Seborrheic dermatitis: Ketoconazole Cream 2% should be applied to the affected area twice daily for four weeks or until clinical clearing.

If a patient shows no clinical improvement after the treatment period, the diagnosis should be redetermined.

HOW SUPPLIED

Ketoconazole Cream 2% is supplied as follows:

15 gram NDC 0168-0099-15
30 gram NDC 0168-0099-30
60 gram NDC 0168-0099-60

Store below 77°F (25°C).

E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747
I299C
R11/11
#39

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 G CONTAINER

NDC 0168-0099-15
FOUGERA®
KETOCONAZOLE
CREAM 2%
For dermatologic use only.
Rx only
Contains ketoconazole 20 mg/g,
propylene glycol, stearyl and cetyl alcohols, sorbitan monostearate,
polysorbate 60, isopropyl myristate,
sodium sulfite anhydrous,
polysorbate 80 and purified water.
NET WT 15 grams
Ketoconazole Cream, 2%
For dermatologic use only.

Dosage: For information for use see accompanying product literature.
Store below 77°F (25°C).
Warning: Not for ophthalmic use.
KEEP OUT OF THE REACH OF CHILDREN.
TO OPEN: Use cap to puncture seal.
IMPORTANT: Do not use if seal has been punctured or is not visible.

Contains ketoconazole 20 mg/g, propylene glycol, stearyl and cetyl alcohols, sorbitan monostearate, polysorbate 60, isopropyl myristate, sodium sulfite anhydrous, polysorbate 80 and purified water.

NET WT 15 grams

See crimp of tube for Control No. & Exp. Date.
E. FOUGERA & CO.
A division of Fougera Pharmaceuticals Inc.
MeVille, New York 11747
U4943E R10/16

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 15 G CARTON
NDC 0168-0099-15
Rx only
FOUGERA®
KETOCONAZOLE
CREAM 2%
For dermatologic use only.
Warning: Not for ophthalmic use.
Keep out of reach of children.
NET WT 15 grams
**KETOCONAZOLE**

ketoconazole cream

<table>
<thead>
<tr>
<th><strong>Product Information</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
<td>HUMAN PRESCRIPTION DRUG</td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
<td>TOPICAL</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Active Ingredient/Active Moiety</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ingredient Name</strong></td>
<td><strong>Basis of Strength</strong></td>
</tr>
<tr>
<td>ketoconazole (UNII: R9400W927I) (ketoconazole - UNII:R9400W927I)</td>
<td>ketoconazole</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Inactive Ingredients</strong></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ingredient Name</strong></td>
<td><strong>Strength</strong></td>
</tr>
<tr>
<td>propylene glycol (UNII: 6DC9Q167V3)</td>
<td></td>
</tr>
<tr>
<td>stearyl alcohol (UNII: 2KR89J4HIY)</td>
<td></td>
</tr>
<tr>
<td>cetyl alcohol (UNII: 936JST6JCN)</td>
<td></td>
</tr>
<tr>
<td>sorbitan monostearate (UNII: NVZ4403E5X)</td>
<td></td>
</tr>
</tbody>
</table>
**Packaging**

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0168-0099-15</td>
<td>1 in 1 CARTON</td>
<td>04/28/2004</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td>15 g in 1 TUBE; Type 0: Not a Combination Product</td>
<td>04/28/2004</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0168-0099-30</td>
<td>1 in 1 CARTON</td>
<td>04/28/2004</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td>30 g in 1 TUBE; Type 0: Not a Combination Product</td>
<td>04/28/2004</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0168-0099-60</td>
<td>1 in 1 CARTON</td>
<td>04/28/2004</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td>60 g in 1 TUBE; Type 0: Not a Combination Product</td>
<td>04/28/2004</td>
<td></td>
</tr>
</tbody>
</table>

**Marketing Information**

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANDA</td>
<td>ANDA076294</td>
<td>04/28/2004</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)

Revised: 6/2018